Please find enclosed transcript of conference call with the investors and analysts held on August 6, 2026

Date: August 12, 2026 To, To, BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Fort, Mumbai – 400001 Bandra (East), Mumbai - 400051 Ref.: BSE Scrip Code No. “540743” Ref.: “GODREJAGRO” Dear Sir / Madam, Sub.: Transcript of Conference call with Investors & Analysts held on Thursday, August 6, 2026 at 3.30 p.m. IST Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing obligations and disclosure Requirements) Regulations, 2015 Please find enclosed herewith a transcript of Conference call of Godrej Agrovet Limited with the Investors and Analysts held on Thursday, August 6, 2026 at 3.30 p.m. IST. The aforesaid information is also available on the website of the Company viz., www.godrejagrovet.com. Please take the same on your records. Thanking you, Yours faithfully, For Godrej Agrovet Limited Vivek Raizada Head – Legal & Company Secretary & Compliance Officer (ACS - 11787) “Godrej Agrovet Limited Q1 FY27 Earnings Conference Call” August 06, 2026 MANAGEMENT: MR. BURJIS GODREJ – CHAIRMAN DESIGNATE – GODREJ AGROVET LIMITED MR. SUNIL KATARIA – CHIEF EXECUTIVE OFFICER AND MANAGING DIRECTOR – GODREJ AGROVET LIMITED MR. S. VARADARAJ – CHIEF FINANCIAL OFFICER – GODREJ AGROVET LIMITED MR. ARIJIT MUKHERJEE – EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER – ASTEC LIFESCIENCES MODERATOR: MR. NITESH DHOOT – ANAND RATHI Page 1 of 20 Godrej Agrovet Limited August 06, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Godrej Agrovet Limited Q1 FY27 Earnings Conference Call hosted by Anand Rathi. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Nitesh Dhoot from Anand Rathi. Thank you, and over to you, sir. Nitesh Dhoot: Thank you, Palak. Good afternoon, everyone, and thank you for joining us on the Godrej Agrovet Q1 FY27 Earnings Conference Call. From the company, we have with us Mr. Burjis Godrej, Chairman Designate; Mr. Sunil Kataria, Chief Executive Officer and Managing Director; Mr. S. Varadaraj, Chief Financial Officer; and Mr. Arijit Mukherjee, Executive Director and Chief Operating Officer, Astec LifeSciences. We would like to begin the call with brief opening remarks from the management, following which we'll have the forum open for an interactive question-and-answer session. Before we start, I would like to point out that some statements made in today's call may be forward-looking, and a disclaimer to this effect has been included in the earnings presentation shared with you earlier. I would now like to invite Mr. Burjis Godrej to make the initial remarks. Over to you, sir. Burjis Godrej: Thank you. Good afternoon, everyone, and welcome to Godrej Agrovet Limited's earnings call for the first quarter of financial year 2027. Thank you for joining us today. During Q1 FY27, we delivered consolidated sales of INR2,852 crores, representing year-on-year growth of 10% despite a challenging operating environment marked by a delayed monsoon and inflationary pressures arising from geopolitical tensions. The quarter saw strong performance in Animal Nutrition and Oil Palm, supported by healthy volumes, improved realizations and operating efficiencies. Our Bangladesh joint venture returned to a broad-based growth trajectory, while Astec sustained its operational recovery and continue to be at EBITDA breakeven. Dairy delivered double-digit revenue growth, led by value-added products and Godrej Foods continued to grow its branded portfolio. Crop Care, however, was affected by the delayed monsoon and slower kharif sowing, which impacted volumes of key products and overall profitability. Coming to the key financial and business highlights of each of our business segments. The Animal Nutrition business delivered a strong quarter with revenue growth of 12.6%, driven by robust demand, improved realizations and 15% growth in cattle feed volumes. Profitability improved significantly with reported segment results growing at 29% and the underlying Page 2 of 20 Godrej Agrovet Limited August 06, 2026 segment results increasing 36%, reflecting the benefits of strategic sourcing, operating leverage and continued cost discipline. The Oil Palm business continued its growth momentum with segment revenue increasing by 28.9% and the segment result growing by 14.4%. Performance was supported by higher CPO and PKO realizations, increased sales volume and improved oil extraction efficiency. The fresh fruit bunch volumes remained broadly stable against a strong comparable quarter, which had benefited from the early onset of the monsoon in the previous year. The stand-alone Crop Care business was impacted by the significant delay in the monsoon and slower kharif sowing following a particularly dry June. This affected demand and resulted in lower volumes of key products, predominantly our in-house cotton herbicide segment. Consequently, segment revenue declined by 16.2%, while the reduction in volumes also led to a contraction in segment margin. At the same time, our portfolio diversification initiatives in this business continued to gain traction. Ashitaka, our maize herbicide and Takai, our paddy insecticide, scaled up during the quarter and received encouraging market acceptance. We also launched Ghassnash in the soybean herbicide category. Astec LifeSciences sustained its recovery momentum and continued at EBITDA breakeven compared with an EBITDA loss of INR11 crores in Q1 FY26. This improvement was driven by margin expansion across both the enterprise and the CDMO category, supported by the turnaround initiatives undertaken over the past year. Revenue was moderately lower due to a change in product mix, but the substantial reduction in losses reflects continued progress in the operational recovery of the business. The dairy business has reported revenue growth of 11.4%, led by healthy volume growth in value-added products. The salience of value-added products increased from 42% to 49% of sales, reflecting sustained consumer demand and progress against our portfolio premiumization strategy. Profitability was affected by elevated milk procurement prices arising from industry-wide constraints in milk availability, together with inflation in certain other inputs. We remain focused on calibrated pricing, procurement efficiencies and cost optimization to mitigate these near-term pressures. Godrej Foods delivered broadly stable revenue despite the planned reduction in live bird volume. Branded volumes grew by approximately 6%, while Yummiez's volumes increased by 22%, in line with our strategy of building a higher-quality branded foods portfolio. Profitability was affected by higher input costs and inflationary pressures related to geopolitical disruptions, which were only partly offset through calibrated pricing actions. Our Bangladesh joint venture, ACI, Godrej Agrovet, also returned to a strong growth trajectory, delivering double-digit growth in volumes, revenue and PBT, supported by broad-based volume expansion and operating leverage. Page 3 of 20 Godrej Agrovet Limited August 06, 2026 Finally, we maintained our focus on balance sheet efficiency and disciplined capital allocation. Our average net working capital improved significantly year-on-year. This improvement supports our objective of strengthening cash generation and enhancing return on capital employed. Moderator: Can you start with the Q&A session, sir? Sunil Kataria: Yes, we can start. Moderator: Okay, sir. Thank you very much. We will now begin the question-and-answer session.Any one who wishes to ask a question may please press * and 1 on their touch tone telephone and if you wish to remove from [Showing first 8,000 characters — download PDF for full document]